

10TH November 2022

To

The Listing Department
Bombay Stock Exchange Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street

Mumbai – 400 001

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Mumbai – 400 051

Trading Symbol: JHS

Scrip Code: 532771

Subject: Outcome of the Board Meeting held on Thursday, 10th November 2022.

Dear Sir,

In terms of Regulation 30 read with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“**Listing Regulations**”), we would like to inform you that the Board of Directors of JHS Svendgaard Laboratories Limited (“**the Company**”) in its meeting held today i.e., Thursday, 10th November 2022, which commenced at 12:00 Noon and concluded at 03:25 P.M inter alia, considered and approved/take note of;

1. Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2022.
2. Limited Review Reports on Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2022.
3. Appointment of Mrs. Komal Jha as Company Secretary & Compliance Officer of the Company w.e.f. 10th November 2022.

Enclosed are the following documents in respect of the items transacted in the meeting:

1. Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2022 (*Annexure-A*).
2. Limited Review Report for Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2022 (*Annexure-B*).

3. The details required under Regulation 30 of the Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 in relation to the appointment of Mrs. Komal Jha (*Annexure- C*)

This disclosure along with the enclosures shall be made available on the website of the Company viz <https://www.svendgaard.com>.

Kindly take the same on records.

Thanking You,

For JHS Svendgaard Laboratories Limited

ASHISH Digitally signed
by ASHISH GOEL
Date: 2022.11.10
15:45:25 +05'30'
GOEL

Ashish Goel
Chief Financial Officer

Encl: A/a

Annexure-C

**Details required under Regulation 30 of the Listing Regulations read with SEBI
Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015**

Particulars	Details
Reason for change	Appointment
Date of Appointment & term of appointment	Mrs. Komal Jha (ACS 20356) has been appointed as an Company Secretary and Compliance officer of the company w.e.f. 10 th November 2022.
Brief profile	Mrs. Komal Jha, Bachelor of Commerce degree with Honour from Delhi University, a Law graduate and Member of the ICSI possesses nearing 15 years' experience in handling listed companies, Stock Exchange and SEBI related matters. He has rich experience in dealing with diversified business industries, Real Estate, Distilleries, Hospitality, Hotels Etc.
Disclosure of relationships	Mrs. Komal Jha does not have any relationship with any of the existing Directors/ Key Managerial Personnel of the Company.

Review Report

To

The Board of Directors
JHS Svendgaard Laboratories Limited
B - 1/E-23, Mohan Co-operative Industrial Estate,
Mathura Road, New Delhi - 110044

1. We have reviewed the Standalone Unaudited Financial Results of JHS Svendgaard Laboratories Limited ("the Company") for the quarter ended 30 September 2022 and the year to date results for the period 1 April 2022 to 30 September 2022, which are included in the accompanying Statement of Standalone Unaudited Financial Results for the quarter and half year ended 30 September 2022, the Standalone Statement of Assets and Liabilities as on that date and the Standalone Statement of Cash Flows for the half year ended on that date ("the Statement"). The Statement has been prepared pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been initialed by us for identification purposes. The Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We draw attention to the following matters:
 - a. The unaudited financial results of the Company for the quarter and half year ended 30 September 2021 and quarter ended 30 June 2022 were reviewed by the predecessor auditor who, vide their reports dated 2 November 2021 and 10 August 2022 respectively, expressed an unmodified conclusion on those financial results.
 - b. The financial information of the Company for the year ended 31 March 2022 included in the Statement, are based on the previously issued financial statements for the years ended 31 March




2022 which were audited by the predecessor auditor who expressed an unmodified opinion vide their report dated 27 May 2022.

Our conclusion is not qualified in respect of these matters.

For **TATTVAM & Co.**

Chartered Accountants

Firm's Registration No. 015048N


Gaurav Saraf

Partner

Membership No. 535309



UDIN: 22535309BCSKBX3261

Place: New Delhi

Date: 10th November 2022

JHS SVENDGAARD LABORATORIES LIMITED

Regd. Office: Trilokpur Road, Kheri (Kala-Amb), Tehsil Nahan, Distt. Sirmour, Himachal Pradesh - 173030, INDIA

CIN-L74110HP2004PLC027558

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2022

(Rs. in lakhs)

S.No.	Particulars	Quarter ended	Quarter ended	Quarter ended	Half Year Ended	Half Year Ended	(Rs. in lakhs)
		Sep 2022	June 2022	Sep 2021	30th Sep 2022	30th Sep 2021	Year Ended 31st March 2022
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income						
	(a) Revenue from operations	2,085.20	1,920.47	2,306.36	4,005.67	4,330.99	7,990.59
	(b) Other income	288.75	118.65	144.42	407.39	371.55	814.39
	Total income	2,373.95	2,039.12	2,450.78	4,413.07	4,702.54	8,804.98
2	Expenses						
	(a) Cost of materials consumed	1,574.45	1,251.97	1,549.92	2,826.42	2,903.78	5,368.24
	(b) Purchases of stock-in-trade	2.31	-	3.95	2.31	61.94	63.97
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(77.56)	149.21	68.21	71.64	181.60	253.45
	(d) Employee benefits expense	236.89	250.92	252.78	487.80	475.93	993.28
	(e) Finance costs	8.29	11.66	11.85	19.95	22.33	49.94
	(f) Depreciation and amortisation expenses	143.84	140.53	150.79	284.37	295.52	589.65
	(g) Other expenses	545.98	363.80	347.33	909.78	646.65	1,294.05
	Total expenses	2,434.20	2,168.09	2,384.83	4,602.27	4,587.75	8,612.59
3	Profit/(loss) before exceptional items and tax (1-2)	(60.25)	(128.97)	65.95	(189.20)	114.79	192.39
4	Exceptional items	-	-	-	-	-	-
5	Profit/(loss) before tax (3+4)	(60.25)	(128.97)	65.95	(189.20)	114.79	192.39
6	Tax expense/(income)						
	Current Tax	-	-	54.57	-	56.83	92.09
	Deferred Tax (including MAT Credit Entitlement)	(1.66)	203.29	(33.34)	201.64	(20.25)	342.97
	Tax for earlier years	-	-	-	-	-	1.50
7	Net Profit/(loss) for the period (5-6)	(58.60)	(332.26)	44.72	(390.85)	78.21	(244.17)
8	Other comprehensive income						
	(a) -Items that will not be reclassified to profit or loss	1.44	1.44	1.64	2.88	3.27	5.76
	-Income tax relating to items that will not be reclassified to profit or loss	(0.40)	(0.40)	(0.46)	(0.80)	(0.91)	(1.60)
	(b) -Items that will be reclassified to profit or loss	-	-	-	-	-	-
	-Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
9	Total comprehensive income for the period (7+8)	(57.56)	(331.22)	45.90	(388.77)	80.57	(240.01)
10	Paid-up equity share capital (Face value per share Rs. 10/-)	6,490.05	6,490.05	6,440.05	6,490.05	6,440.05	6,490.05
11	Reserve excluding revaluation reserves as per balance sheet of previous accounting year						
12	Earnings per equity share						
	(a) Basic (Rs.)	(0.09)	(0.51)	0.12	(0.60)	0.12	(0.38)
	(b) Diluted (Rs.)	(0.09)	(0.51)	0.12	(0.60)	0.12	(0.38)



Standalone Statement of Assets and Liabilities

(Rs. in lakhs)

	Particulars	As at 30th	As at 31st March
		September 2022	2022
		Unaudited	Audited
A	ASSETS		
	Non-current assets		
	(a) Property, plant and equipment	5,422.07	5,418.43
	(b) Capital work-in-progress	1,385.83	1,582.69
	(c) Right-of-use assets	110.05	122.39
	(d) Intangible assets	0.07	0.09
	(e) Financial Assets		
	(i) Investments	1,421.00	1,421.00
	(ii) Other Investments	145.45	117.63
	(iii) Loans	(0.00)	(0.00)
	(iv) Others	427.68	420.32
	(f) Deferred Tax Assets (net)	5.69	208.13
	(g) Non-current tax assets (net)	129.55	117.11
	(h) Other non-current assets	4,662.73	3,228.95
	Total non-current assets	13,710.12	12,636.73
	Current assets		
	(a) Inventories	1,166.33	914.91
	(b) Financial Assets		
	(i) Investments	50.94	-
	(ii) Trade receivables	1,427.48	1,618.58
	(iii) Cash and cash equivalents	604.40	430.76
	(iv) Bank balances other than (iii) above	103.45	117.16
	(v) Loans	2,744.60	3,822.99
	(vi) Others	253.04	543.19
	(c) Other current assets	1,045.41	1,024.56
	Total current assets	7,395.65	8,472.17
	Total assets	21,105.77	21,108.91
B	EQUITY AND LIABILITIES:		
	Equity		
	(a) Equity Share Capital	6,490.05	6,490.05
	(b) Other Equity	12,097.75	12,486.55
	(c) Non-Controlling Interests		
	Total equity	18,587.80	18,976.59
	Liabilities		
	Non-current liabilities		
	(a) Financial liabilities		
	(i) Borrowings	29.09	36.56
	(ii) Lease liabilities	141.38	141.88
	(b) Provisions	161.60	149.48
	(c) Other non-current liabilities	-	143.99
	Total non-current liabilities	332.07	471.91
	Current liabilities		
	(a) Financial liabilities		
	(i) Borrowings	13.55	18.11
	(ii) Trade payables		
	- total outstanding dues of micro and small enterprises	177.30	196.04
	- total outstanding dues of creditors other than micro and small enterprises	1,492.72	1,113.74
	(iii) Lease Liabilities	21.37	19.91
	(iii) Other financial liabilities	221.83	187.70
	(b) Other current liabilities	237.82	103.57
	(c) Provisions	21.33	21.33
	Total current liabilities	2,185.91	1,660.40
	Total liabilities	2,517.97	2,132.32
	Total equity and liabilities	21,105.77	21,108.91



JHS SVENDGAARD LABORATORIES LIMITED
STATEMENT OF STANDALONE CASH FLOWS FOR THE HALF YEAR ENDED 30th September, 2022

(₹ in lakhs)

Particulars	Half Year ended 30 September 2022 (Unaudited)	Half Year ended 30 September 2021 (Unaudited)
A. Cash Flow from Operating Activities		
Profit before exceptional items and tax	(189.19)	114.79
Adjustments for:		
Provision/ write-back for inventory (net)	(4.63)	(37.08)
Depreciation and Amortization	284.37	295.52
Loss on disposal of Property Plant and Equipment (Net)	7.44	-
Interest income	(148.59)	(88.58)
Government grant amortization	(7.83)	(55.49)
Provision no longer required written back	-	(4.82)
Balances and advances written off	-	23.70
Balances and advances written back	-	(113.44)
Profit on sale of Investment	-	(0.62)
Interest and finance Charges	19.95	22.33
Exchange(gain)/loss (net)	(24.31)	(41.64)
Amortization of deferred rent expense	1.12	-
Net gain on financial asset mandatorily measured at FVTPL	(1.81)	-
Operating profit before working capital changes	(63.47)	114.67
Adjustments for :		
(Increase)/Decrease in inventories	(251.42)	(36.60)
(Increase)/Decrease in trade receivables	191.11	2,940.51
(Increase)/Decrease in Current Loans	1,078.40	13.97
(Increase)/Decrease in Other Current Assets	(20.85)	(309.27)
(Increase)/Decrease in current investment	(50.94)	-
(Increase)/Decrease in Other Non Current Financial assets	(7.36)	(960.96)
(Increase)/Decrease in Other Current financial Assets	290.15	(99.12)
(Increase)/Decrease in Non current Loans	-	(1,115.25)
(Increase)/Decrease in Other non-current assets	(1,446.22)	(1,689.04)
Increase/ (decrease) in Non Current financial liabilities	(143.99)	(67.02)
Increase/ (decrease) in Trade payables	360.24	(205.52)
Increase/ (decrease) in Lease Liabilities (Current)	0.95	(8.90)
Increase/ (decrease) in Short term provisions	-	1.04
Increase/ (decrease) in Long term provisions	12.12	11.23
Increase/ (decrease) in Borrowing provisions	(12.03)	-
Increase/ (decrease) in Other Current liabilities	168.95	264.34
Cash (used) from operations	105.64	(1,145.92)
Taxes Paid	-	(56.83)
Cash flow from exceptional items		
Loss on asset held for sale	-	-
Net cash generated/(used) from operating activities	105.64	(1,202.75)
B. Cash Flow from Investing Activities		
Purchase of Property Plant and Equipment	(75.06)	(203.88)
Proceeds from Mutual funds	50.94	(50.00)
Investments in Mutual funds	(27.82)	-
Interest income received	148.59	88.58
Change in Other bank balance and cash not available for immediate use	13.72	7.63
Net Cash generated/(used) in investing activities	110.37	(157.67)



C. Cash Flow from Financing Activities		
Proceeds from/ (repayment of) long term borrowings	(19.95)	(10.34)
Proceeds from/ (repayment of) short term borrowings	-	(8.32)
Repayment of lease liabilities	(22.43)	(22.43)
Interest and financial charges	-	(22.33)
Net increase from financing activities	(42.37)	(63.41)
Net Increase/(decrease) in cash and cash equivalents	173.64	(1,423.85)
Opening balance of cash and cash equivalents	430.76	1,652.53
Closing balance of cash and cash equivalents	604.40	228.68
Components of cash and cash equivalents as at end of the year		
Cash on hand	51.39	23.71
Balances with banks		
- on current account	550.82	202.79
- in term deposits with original maturity of 3 months or less	2.20	2.18
Cash and bank balance	604.40	228.68



Notes:

- 1 The above unaudited standalone financial results for the quarter and half year ended 30th September 2022 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 10th November, 2022. The statutory auditors have expressed unmodified opinion in the limited review report on these standalone financial results.
- 2 The standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 3 In line with the provisions of Ind AS 108 - Operating Segments and on the basis of the review of operations being done by the Management, the operations of the Company fall under Manufacturing of Oral Care products, which is considered to be the only reportable segment by the management.
- 4 The Company in its board meeting held on 09th October, 2020 has approved the Composite Scheme of Arrangement for Amalgamation and Demerger between among JHS Svendgaard Laboratories Limited (Demerged Company/ Transferee Company), JHS Svendgaard Retail Ventures Private Limited (Resulting Company) and JHS Svendgaard Brands Limited (Transferor Company) ("Composite Scheme") under Section 230-232 of the Companies Act, 2013. Thereafter, on 8th December, 2021, both the stock exchanges viz. BSE Limited and National Stock Exchange of India Limited had granted their no-objection to the Composite Scheme. At present, the application for approval of the said Composite Scheme is pending before Hon'ble NCLT, Chandigarh.
- 5 Pursuant to approval of shareholders by way of special resolution in accordance with section 42 & 62 of the Companies Act, 2013 and Rules made thereunder and as per SEBI (ICDR) Regulations, 2018 the Company approved preferential allotment of 1,55,00,000 fully convertible warrants on preferential basis to person(s) belonging to promoter & promoter group and non-promoter category at an issue price of Rs. 26.60/- (Rupees Twenty-Six and Sixty Paise Only) per warrant. The company is in the process of obtaining the in-principal approval from the stock exchange.
- 6 Previous period figures have been re-grouped / re-classified wherever necessary, to conform to current period's classification or also in order to comply with the requirements of the amended Schedule III to the Companies Act, 2013 effective 1st April, 2021.

Place : New Delhi

Date : 10th November, 2022

For and on behalf of Board of Directors

Nikhil Nanda
Managing Director
DIN : 00051501





Review Report

To

The Board of Directors
JHS Svendgaard Laboratories Limited
B - 1/E-23, Mohan Co-operative Industrial Estate,
Mathura Road, New Delhi - 110044

1. We have reviewed the Consolidated Unaudited Financial Results of JHS Svendgaard Laboratories Limited ("the Parent") and its subsidiaries (the parent and its subsidiaries hereinafter referred to as the "Group"), [refer Note 3 on the Statement] for the quarter ended 30 September 2022 and the year to date results for the period 1 April 2022 to 30 September 2022, which are included in the accompanying Statement of Consolidated Unaudited Financial Results for the quarter and half year ended 30 September 2022, the Consolidated Statement of Assets and Liabilities as on that date and the Consolidated Statement of Cash Flows for the half year ended on that date ("the Statement"). The Statement is being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been initialed by us for identification purposes.
2. The Statement, which is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



4. The Statement includes the results of the following entities:

Sr.no.	Name of Entities	Relationship
1	JHS Svendgaard Laboratories Limited	Parent
2	JHS Svendgaard Brands Limited (formerly known as JHS Svendgaard Dental Care Limited)	Subsidiary by virtue of Control
3	JHS Svendgaard Mechanical and Warehouse Private Limited	Subsidiary
4	JHS Svendgaard Retail Ventures Private Limited	Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial statements of three subsidiaries included in the Statement, whose interim financial statements reflects total revenues of Rs. 656.07 lakhs, total net loss after tax of Rs. (65.69) lakhs and total comprehensive income of Rs. (64.77) lakhs for the quarter ended 30 September 2022, as considered in the Statement. These interim financial statements have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matters.

7. We draw attention to the following matters:
- a. The consolidated unaudited financial results of the Group for the quarter and half year ended 30 September 2021 and quarter ended 30 June 2022 were reviewed by the predecessor auditor who, vide their reports dated 2 November 2021 and 10 August 2022 respectively, expressed an unmodified conclusion on those financial results. The unaudited financial results of the subsidiaries as listed in paragraph 4 consisted in the consolidated unaudited financial results of the Group for the quarter and half year ended 30 September 2021 and quarter ended 30 June 2022 were reviewed by another firms of chartered accountants who, vide their respective reports expressed an unmodified conclusion on those financial results.
- b. The comparative financial information of the Group for the year ended 31 March 2022 included in the Statement, are based on the previously issued financial statements for the years ended 31 March 2022 which were audited by the predecessor auditors who expressed an unmodified opinion vide their report dated 27 May 2022. The audited financial results of the subsidiaries as listed in paragraph 4 consisted in the comparative financial information of the Group for the year ended 31





March 2022 were audited by another firms of chartered accountants who, vide their respective reports expressed an unmodified opinion on those financial results.

Our conclusion is not qualified in respect of these matters.

For **TATTVAM & Co.**

Chartered Accountants

Firm's Registration No. 015048N

Gaurav Saraf

Partner

Membership No. 535309



UDIN: 22535309BCSLFO7837

Place: New Delhi

Date: 10th November 2022



JHS SVENDGAARD LABORATORIES LIMITED

Regd. Office: Trilokpur Road, Kheri (Kala-Amb), Tehsil Nahan, Distt. Sirmour, Himachal Pradesh - 173030, INDIA

CIN-L74110HP2004PLC027558

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2022

		(Rs. in lakhs)					
S.No.	Particulars	Quarter Ended 30th Sep 2022	Quarter Ended 30th June 2022	Quarter Ended 30th Sep 2021	Half Year Ended 30th Sep 2022	Half Year Ended 30th Sep 2021	Year Ended 31st March 2022
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income						
	(a) Revenue from operations	2,405.29	2,130.87	2,463.88	4,536.16	4,622.42	8,625.24
	(b) Other income	343.80	147.74	169.29	491.54	427.05	938.99
	Total income	2,749.09	2,278.61	2,633.17	5,027.70	5,049.47	9,564.23
2	Expenses						
	(a) Cost of materials consumed	1,574.45	1,251.98	1,515.91	2,826.42	2,903.79	5,368.24
	(b) Purchase of stock-in-trade	95.91	133.66	94.76	229.58	162.81	419.84
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(78.13)	160.87	41.85	82.74	198.95	262.17
	(d) Employee benefits expense	403.11	335.70	295.63	738.81	554.66	1,144.56
	(e) Finance Costs	18.77	21.98	26.79	40.75	51.16	139.36
	(f) Depreciation and amortisation expense	174.16	170.20	185.85	344.36	365.30	705.22
	(g) Other expenses	658.85	440.86	402.06	1,099.71	758.39	1,514.54
	Total expenses	2,847.12	2,515.25	2,562.85	5,362.37	4,995.06	9,553.93
3	Profit / (Loss) before exceptional Items and tax (1-2)	(98.03)	(236.64)	70.32	(334.67)	54.42	10.30
4	Exceptional items			-	-		-
5	Profit / (Loss) before tax (3+4)	(98.03)	(236.64)	70.32	(334.67)	54.42	10.30
6	Tax expense/(income)						
	Current Tax	-	-	54.57	-	56.83	92.09
	Deferred Tax (including MAT Credit Entitlement)	(57.30)	179.17	(31.27)	121.87	(20.87)	345.65
	Tax for earlier years			-	-		1.50
7	Net Profit / (Loss) for the period (5-6)	(40.73)	(415.81)	47.01	(456.54)	18.46	(428.94)
8	Other comprehensive income						
	(a) -Items that will not be reclassified to profit or loss	1.44	2.69	3.02	4.13	6.03	10.75
	-Income tax relating to items that will not be reclassified to profit or loss	(0.40)	(0.73)	(0.81)	(1.13)	(1.63)	(2.90)
	(b) -Items that will be reclassified to profit or loss	-	-	-	-	-	-
	-Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
9	Total comprehensive income (7+8)	(39.68)	(413.83)	49.23	(453.54)	22.86	(421.09)
	Net profit attributable to:						
	Owners of the Company	(21.63)	(384.53)	26.59	(406.16)	4.05	(405.19)
	Non-controlling interest	(19.10)	(31.27)	20.44	(50.37)	14.41	(23.74)
	Other Comprehensive Income attributable to:						
	Owners of the Company	1.04	1.43	1.62	2.47	3.22	5.73
	Non-controlling interest	-	0.53	0.58	0.53	1.17	2.12
	Total Comprehensive Income attributable to:						
	Owners of the Company	(20.59)	(383.10)	28.19	(403.69)	7.27	(399.46)
	Non-controlling interest	(19.10)	(30.74)	21.01	(49.84)	15.57	(21.63)
10	Paid-up equity share capital (Face value per share Rs. 10/-)	6,490.05	6,490.05	6,440.05	6,490.05	6,440.05	6,490.05
11	Reserve excluding revaluation reserves as per balance sheet of previous accounting year					12,483.97	
12	Earnings per equity share						
	(a) Basic (Rs.)	(0.03)	(0.59)	0.05	(0.63)	0.01	(0.63)
	(b) Diluted (Rs.)	(0.03)	(0.59)	0.05	(0.63)	0.01	(0.63)



Consolidated Statement of Assets and Liabilities

(Rs. in lakhs)

	Particulars	As at 30th September 2022	As at 31st March 2022
		Unaudited	Audited
A	ASSETS		
	Non-current assets		
	(a) Property, plant and equipment	5,461.70	5,467.97
	(b) Capital work-in-progress	1,798.55	1,995.89
	(c) Right-of-use assets	214.04	271.06
	(d) Goodwill	110.69	110.69
	(e) Other Intangible assets	1.40	2.21
	(f) Financial Assets		
	(i) Other Investments	145.45	117.63
	(ii) Loans	427.68	420.32
	(iii) Others	5.44	5.44
	(g) Non-current tax assets (net)	129.55	117.11
	(h) Deferred Tax Assets (net)	523.76	649.73
	(i) Other non-current assets	5,720.55	5,146.03
	Total non-current assets	14,538.81	14,304.09
	Current assets		
	(a) Inventories	1,461.01	1,210.24
	(b) Financial Assets		
	(i) Investments	1,029.18	243.98
	(ii) Trade receivables	1,918.39	1,811.62
	(iii) Cash and cash equivalents	782.48	528.81
	(iv) Bank balances other than (iii) above	103.97	117.42
	(v) Loans	709.73	1,522.79
	(vi) Others	254.11	544.26
	(c) Current tax assets	2.15	2.15
	(d) Other current assets	1,629.35	1,913.83
	(e) Assets classified as held for sale	-	-
	Total current assets	7,890.38	7,895.10
	Total assets	22,429.19	22,199.18
B	EQUITY AND LIABILITIES:		
	Equity		
	(a) Equity Share Capital	6,490.05	6,490.05
	(b) Other Equity	11,704.20	12,100.16
	(c) Non-Controlling Interests	885.93	914.34
	Total equity	19,080.18	19,504.56
	Liabilities		
	Non-current liabilities		
	(a) Financial liabilities		
	(i) Borrowings	69.92	48.20
	(ii) Lease Liabilities	431.54	457.58
	(b) Provisions	167.19	153.92
	(c) Other non current liabilities	-	143.99
	Total non-current liabilities	668.65	803.70
	Current liabilities		
	(a) Financial liabilities		
	(i) Borrowings	15.22	20.35
	(ii) Trade payables		
	- total outstanding dues of micro and small enterprises	177.30	196.04
	- total outstanding dues of creditors other than micro and small enterprises	1,680.98	1,187.76
	(iii) Lease liabilities	126.34	92.04
	(iii) Other financial liabilities	219.60	240.44
	(b) Other current liabilities	439.42	132.80
	(c) Provision	21.48	21.48
	Total current liabilities	2,680.35	1,890.91
	Total liabilities	3,349.00	2,694.62
	Total equity and liabilities	22,429.19	22,199.18



JHS SVENDGAARD LABORATORIES LIMITED
CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTMEBER, 2022

(₹ in lakhs)

Particulars	Half Year ended 30 September, 2022 (Un-audited)	Half Year ended 30 September, 2021 (Un-audited)
A. Cash Flow from Operating Activities		
Profit before exceptional items and tax	(323.56)	54.41
Adjustments for:		
Provision/ write-back for inventory (net)	(4.63)	(37.08)
Depreciation and Amortization	344.37	365.29
(Profit)/Loss on disposal of Property Plant and Equipment (Net)	7.44	-
Interest income	(150.14)	(93.52)
Interest income - ind As Adjustment	-	-
Government grant amortization	(7.83)	(55.49)
Provision no longer required written back	-	(4.82)
Balances and Advances written off	-	23.70
Re- measurment Gains	(2.04)	(2.16)
Security deposit for advance rental as per Ind AS 109	-	(6.71)
Ammortisation expense of security deposit	-	6.75
Amortization of deferred rent expense	1.12	-
Balances and Advances written back	-	(115.03)
Profit on sale of investment	-	(0.62)
Interest and finance Charges	121.00	31.49
Net gain on financial asset mandatorily measured at FVTPL	(1.81)	-
Exchange(gain)/loss (net)	(24.34)	(41.64)
Fair value adjustments	0.40	-
Others	-	0.40
Other Consolidation adjustment	-	3.87
Operating profit before working capital changes	(40.02)	128.82
Adjustments for :		
(Increase)/Decrease in inventories	(257.77)	(19.25)
(Increase)/Decrease in trade receivables	(184.76)	2,863.76
(Increase)/Decrease in Current Loans	800.20	(104.70)
(Increase)/Decrease in Other Current Assets	173.93	(762.91)
(Increase)/Decrease in current investment	(50.94)	-
Investment in bank deposits (having original maturity of more than 3 months)	-	(960.96)
(Increase)/Decrease in Other Non Current Financial assets-Others	(7.52)	-
(Increase)/Decrease in Other Current Financial assets	295.04	(100.65)
(Increase)/Decrease in Non current Loans	101.33	(1,125.70)
(Increase)/Decrease in Other non-current assets	(482.11)	(363.26)
Increase/ (decrease) in Other Current Financial Liabilities	(57.19)	(62.21)
Increase/ (decrease) in Trade payables	510.67	(153.94)
Increase/ (decrease) in Lease Liabilities	0.95	(8.90)
Increase/ (decrease) in Other Non Current Financial Liabilities	(30.58)	-
Increase/ (decrease) in Short term provisions	-	1.04
Increase/ (decrease) in Short term borrowing	(12.60)	-
Increase/ (decrease) in Long term provisions	14.52	15.36
Increase/ (decrease) in Non Current financial liabilities	(143.99)	(151.69)
Increase/ (decrease) in Other Current liabilities	253.09	479.77
Increase/ (decrease) in Other non-Current liabilities	(10.85)	(1,330.42)
Cash (used) from operations	870.81	(1,655.82)
Taxes Paid	-	(56.83)
Cash flow from exceptional items		
Loss on asset held for sale	-	-
Net cash generated/(used) from operating activities	870.81	(1,712.65)
B. Cash Flow from Investing Activities		
Purchase of Property Plant and Equipment	(32.92)	(205.70)



Right-of-use	97.27	32.95
Proceeds from sale of Property Plant and Equipment	-	-
Purchase of Mutual Funds	(55.54)	(50.00)
Proceeds from Mutual funds	50.94	(2.17)
Net Proceeds from Investment	(745.52)	-
Interest income received	144.88	88.26
Change in Other bank balance and cash not available for immediate use	58.62	7.63
Net Cash generated/(used) in investing activities	(482.25)	(129.02)
C. Cash Flow from Financing Activities		
Proceeds from/ (repayment of) long term borrowings	(20.75)	(11.74)
Proceeds from/ (repayment of) short term borrowings	5.67	(2.64)
Repayment of lease liabilities	(18.79)	118.14
Interest and financial charges	(101.02)	(31.45)
Net increase from financing activities	(134.89)	72.31
Net Increase/(decrease) in cash and cash equivalents	253.67	(1,769.39)
Opening balance of cash and cash equivalents	528.81	2,079.24
Closing balance of cash and cash equivalents	782.48	309.85
Components of cash and cash equivalents as at end of the year		
Cash on hand	69.68	33.73
Balances with banks		
- on current account	710.60	273.94
- in term deposits with original maturity of 3 months or less	2.20	2.18
Cash and bank balance	782.48	309.85



JHS SVENDGAARD LABORATORIES LIMITED
CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTMEBER, 2022

(₹ in lakhs)

Particulars	Half Year ended 30 September, 2022 (Un-audited)	Half Year ended 30 September, 2021 (Un-audited)
A. Cash Flow from Operating Activities		
Profit before exceptional items and tax	(323.56)	54.41
Adjustments for:		
Provision/ write-back for inventory (net)	(4.63)	(37.08)
Depreciation and Amortization	344.37	365.29
(Profit)/Loss on disposal of Property Plant and Equipment (Net)	7.44	-
Interest income	(150.14)	(93.52)
Interest income - ind As Adjustment	-	-
Government grant amortization	(7.83)	(55.49)
Provision no longer required written back	-	(4.82)
Balances and Advances written off	-	23.70
Re- measurement Gains	(2.04)	(2.16)
Security deposit for advance rental as per Ind AS 109	-	(6.71)
Ammortisation expense of security deposit	-	6.75
Amortization of deferred rent expense	1.12	-
Balances and Advances written back	-	(115.03)
Profit on sale of investment	-	(0.62)
Interest and finance Charges	121.00	31.49
Net gain on financial asset mandatorily measured at FVTPL	(1.81)	-
Exchange(gain)/loss (net)	(24.34)	(41.64)
Fair value adjustments	0.40	-
Others	-	0.40
Other Consolidation adjustment	-	3.87
Operating profit before working capital changes	(40.02)	128.82
Adjustments for :		
(Increase)/Decrease in inventories	(257.77)	(19.25)
(Increase)/Decrease in trade receivables	(184.76)	2,863.76
(Increase)/Decrease in Current Loans	800.20	(104.70)
(Increase)/Decrease in Other Current Assets	173.93	(762.91)
(Increase)/Decrease in current investment	(50.94)	-
Investment in bank deposits (having original maturity of more than 3 months)	-	(960.96)
(Increase)/Decrease in Other Non Current Financial assets-Others	(7.52)	-
(Increase)/Decrease in Other Current Financial assets	295.04	(100.65)
(Increase)/Decrease in Non current Loans	101.33	(1,125.70)
(Increase)/Decrease in Other non-current assets	(482.11)	(363.26)
Increase/ (decrease) in Other Current Financial Liabilities	(57.19)	(62.21)
Increase/ (decrease) in Trade payables	510.67	(153.94)
Increase/ (decrease) in Lease Liabilities	0.95	(8.90)
Increase/ (decrease) in Other Non Current Financial Liabilities	(30.58)	-
Increase/ (decrease) in Short term provisions	-	1.04
Increase/ (decrease) in Short term borrowing	(12.60)	-
Increase/ (decrease) in Long term provisions	14.52	15.36
Increase/ (decrease) in Non Current financial liabilities	(143.99)	(151.69)
Increase/ (decrease) in Other Current liabilities	253.09	479.77
Increase/ (decrease) in Other non-Current liabilities	(10.85)	(1,330.42)
Cash (used) from operations	870.81	(1,655.82)
Taxes Paid	-	(56.83)
Cash flow from exceptional items		
Loss on asset held for sale	-	-
Net cash generated/(used) from operating activities	870.81	(1,712.65)
B. Cash Flow from Investing Activities		
Purchase of Property Plant and Equipment	(32.92)	(205.70)



Right-of-use	97.27	32.95
Proceeds from sale of Property Plant and Equipment	-	-
Purchase of Mutual Funds	(55.54)	(50.00)
Proceeds from Mutual funds	50.94	(2.17)
Net Proceeds from Investment	(745.52)	-
Interest income received	144.88	88.26
Change in Other bank balance and cash not available for immediate use	58.62	7.63
Net Cash generated/(used) in Investing activities	(482.25)	(129.02)
C. Cash Flow from Financing Activities		
Proceeds from/ (repayment of) long term borrowings	(20.75)	(11.74)
Proceeds from/ (repayment of) short term borrowings	5.67	(2.64)
Repayment of lease liabilities	(18.79)	118.14
Interest and financial charges	(101.02)	(31.45)
Net increase from financing activities	(134.89)	72.31
Net Increase/(decrease) in cash and cash equivalents	253.67	(1,769.39)
Opening balance of cash and cash equivalents	528.81	2,079.24
Closing balance of cash and cash equivalents	782.48	309.85
Components of cash and cash equivalents as at end of the year		
Cash on hand	69.68	33.73
Balances with banks		
- on current account	710.60	273.94
- in term deposits with original maturity of 3 months or less	2.20	2.18
Cash and bank balance	782.48	309.85



Notes:

- The above unaudited consolidated financial results for the quarter and half year ended 30th september 2022 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 10th November , 2022. the statutory auditors have expressed unmodified opinion in the limited review report on these consolidated financial results.
- The consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- The consolidated financials results of the Group include financials of three subsidiaries namely JHS Svendgaard Brands Limited (formerly known as JHS Svendgaard Dental Care Limited), JHS Svendgaard Mechanical and Warehouse Private Limited & JHS Svendgaard Retail Ventures Private Limited. The details of ownership is given as below :-

Particulars	As on 30th September , 2022	As on 31st March , 2022
JHS Svendgaard Brands Limited *	42.68%	42.68%
JHS Mechanical and Warehouse Private Limited	99.99%	99.99%
JHS Svendgaard Retail Ventures Private Limited	99.82%	99.82%

* JHS Svendgaard Brands Limited has been consolidated as per the requirement of Ind As 110 "Consolidated financial statements" as it meets the criteria of "Control" definition as given in the standard .There are no changes except shareholding in the results as it was considered as subsidiary in earlier years.

- In line with the provisions of Ind AS 108 - Operating Segments and on the basis the review of operations being done by the Management, The Following disclosures have been made to enable users of financials instruments for better understanding of business of group.

Particulars	Quarter Ended 30th September 2022	Quarter Ended 30th June 2022	Quarter Ended 30th September 2021	Half Year Ended 30th September 2022	Half Year Ended 30th September 2021	Year Ended 31st March 2022
Segment Revenue						
Manufacturing business	2,085.20	1,920.47	2,306.37	4,005.67	4,330.99	7,990.59
Other than manufacturing	101.51	108.79	158.16	210.31	258.30	498.20
Retail business	299.85	145.91	53.64	445.76	99.13	274.55
Less: Inter segment revenue	(81.27)	(44.30)	(54.29)	(125.58)	(65.99)	(138.11)
Segment Results						
Manufacturing business	(58.60)	(332.26)	44.74	(390.84)	78.22	(244.16)
Other than manufacturing	(33.50)	(54.62)	35.74	(88.14)	25.25	(41.55)
Retail business	50.84	(20.37)	(34.60)	30.45	(76.41)	(134.67)
Less: Inter segment result	0.52	(8.55)	1.12	(8.02)	(8.60)	(8.56)
Segment Assets						
Manufacturing business	21,105.77	21,005.08	21,680.42	21,105.77	21,680.42	21,108.91
Other than manufacturing	6,240.96	6,277.40	3,511.60	6,240.96	3,511.60	6,247.06
Retail business	1,018.60	704.02	760.54	1,018.60	760.54	745.12
Less: Inter segment assets	(5,936.15)	(5,961.53)	(2,694.04)	(5,936.15)	(2,694.04)	(5,901.91)
Segment Liabilities						
Manufacturing business	2,517.97	2,359.73	2,456.17	2,517.97	2,456.17	2,132.32
Other than manufacturing	4,771.31	4,774.57	1,890.04	4,771.31	1,890.04	4,690.65
Retail business	597.94	382.46	332.27	597.94	332.27	375.09
Less: Inter segment liabilities	(4,538.22)	(4,530.80)	(1,295.52)	(4,538.22)	(1,295.52)	(4,503.44)

- The Company in its board meeting held on 09th October, 2020 has approved the Composite Scheme of Arrangement for Amalgamation and Demerger between among JHS Svendgaard Laboratories Limited (Demerged Company/ Transferee Company), JHS Svendgaard Retail Ventures Private Limited (Resulting Company) and JHS Svendgaard Brands Limited (Transferor Company) ('Composite Scheme') under Section 230-232 of the Companies Act, 2013. Thereafter, on 8th December, 2021, both the stock exchanges viz. BSE Limited and National Stock Exchange of India Limited had granted their no-objection to the Composite Scheme. At present, the application for approval of the said Composite Scheme is pending before Hon'ble NCLT, Chandigarh.
- Pursuant to approval of shareholders by way of special resolution in accordance with section 42 & 62 of the Companies Act, 2013 and Rules made thereunder and as per SEBI (ICDR) Regulations, 2018 the Company approved preferential allotment of 1,55,00,000 fully convertible warrants on preferential basis to person(s) belonging to promoter & promoter group and non-promoter category at an issue price of Rs. 26.60/- (Rupees Twenty-Six and Sixty Paise Only) per warrant. The company is in the process of obtaining the in-principal approval from the stock exchange.
- Previous period figures have been re-grouped / re-classified wherever necessary, to conform to current period's classification or also in order to comply with the requirements of the amended Schedule III to the Companies Act, 2013 effective 1st April, 2021.

Place : New Delhi
Date : 10th November,2022

For and on behalf of Board of Directors

Nikhil Nanda
Managing Director
DIN : 00051501

